ANONC
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Advance Zinctek Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Advance Nanotek Limited - Ordinary Fully Paid Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ANONC
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in ANONC
N/A
ANONC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in ANONC also invest in...
Want more shares? Try these...
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The firm's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. Its ATL1103 is in clinical development for acromegaly. The firm's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The firm completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The firm is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
🙌 Performance (5Yr p.a)
21.43%
📊 Share price
$0.06 AUD
NULL PHARMACEUTICALS
